Journal of Clinical Oncology
Journal
-
- Overview
-
- Identity
-
- View All
-
Overview
publication venue for
-
Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer.
33:2609-2616.
2015
-
Adherence to CONSORT adverse event reporting guidelines in randomized clinical trials evaluating systemic cancer therapy: A systematic review.
31:3957-3963.
2013
-
BRAF inhibitor-driven tumor proliferation in akras-mutated colon carcinoma is not overcome by mek1/2 inhibition.
31:e448-e451.
2013
-
Consistency in the analysis and reporting of primary end points in oncology randomized controlled trials from registration to publication: a systematic review.
30:210-216.
2012
-
Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer.
30:1505-1512.
2012
-
Reply to D.J. Stewart.
28:e651-e651.
2010
-
Randomized Phase II Trials: Inevitable or Inadvisable?.
28:2641-2647.
2010
-
Reporting of Time-to-Event End Points and Tracking of Failures in Randomized Trials of Radiotherapy With or Without Any Concomitant Anticancer Agent for Locally Advanced Head and Neck Cancer.
27:5965-5971.
2009
-
Staging (18)FDG-PET in newly diagnosed small cell lung cancer (SCLC): 15-year institutional experience..
27:e19044.
2009
-
Is It Feasible and Desirable to Collect Voluntarily Quality and Outcome Data Nationally in Palliative Oncology Care?.
26:3853-3859.
2008
-
Activity of Sunitinib in Patients With Advanced Neuroendocrine Tumors.
26:3403-3410.
2008
-
Relationship of Hepatic Functional Imaging to Irinotecan Pharmacokinetics and Genetic Parameters of Drug Elimination.
24:4228-4235.
2006
-
Radioimmunotherapy of Prostate Cancer: Does Tumor Size Matter?.
23:4567-4569.
2005
-
Use of Adjuvant Chemotherapy and Radiation Therapy for Rectal Cancer Among the Elderly: A Population-Based Study.
20:2643-2650.
2002
-
Outcomes of Tamoxifen Chemoprevention for Breast Cancer in Very High-Risk Women: A Cost-Effectiveness Analysis.
20:9-16.
2002
-
Outcomes of tamoxifen chemoprevention for breast cancer in very high-risk women: A cost-effectiveness analysis.
20:9-16.
2002
-
Variations in the Use of Chemotherapy for Elderly Patients With Advanced Ovarian Cancer: A Population-Based Study.
20:173-178.
2002
-
Variations in the Use of Chemotherapy for Elderly Patients With Advanced Ovarian Cancer: A Population-Based Study.
20:173-178.
2002
-
Specific Targeting, Biodistribution, and Lack of Immunogenicity of Chimeric Anti-GD3 Monoclonal Antibody KM871 in Patients With Metastatic Melanoma: Results of a Phase I Trial.
19:3976-3987.
2001
-
Increased Temperature of Malignant Urinary Bladder Tumors In Vivo: The Application of a New Method Based on a Catheter Technique.
19:676-681.
2001
-
Phase I/II study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancer..
14:1787-1797.
1996
-
Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer..
12:1561-1571.
1994
-
Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts..
12:1193-1203.
1994
-
Systematic review and network meta-analysis of treatment outcomes for multiple myeloma
2017
-
Dexamethasone for cancer-related fatigue
2014
-
Ketamine and Cancer Pain: The Reports of My Death Have Been Greatly Exaggerated
2013
-
A phase II study of docetaxel-carboplatin as first line therapy in the patients with visceral metastatic breast cancer- a Bangladesh experience
2006
-
Clinical experience of using docetaxel-cisplatin in the treatment of advanced ovarian cancer: a Bangladesh perspective
2006
-
A phase II clinical trial of ipilimumab/nivolumab combination immunotherapy in patients with rare upper gastrointestinal, neuroendocrine, and gynecological malignancies.
2019
-
ABT-806 derived antibody drug conjugates (ADCs) inhibit growth of malignant mesothelioma in-vivo.
2019
-
Patient reported outcome measures (PROMs) in patients (pts) with locally advanced rectal cancer (LARC) managed with a watch and wait (W&W) approach after a clinical complete response to chemoradiotherapy (CRT).
2019
-
Phase II study to evaluate safety and efficacy of MEDI4736 (durvalumab) + radiotherapy in patients with newly diagnosed unmethylated MGMT glioblastoma (new unmeth GBM).
2019
-
FPT155-001: A phase Ia/Ib study of FPT155 (CD80-FC) in patients with advanced solid tumors.
2019
-
Preliminary results from patients with urothelial carcinoma (UC) in a phase 1A/1B study of bgb-A317, an anti-PD-1 monoclonal antibody.
2018
-
A multicenter, 3-arm, open-label, phase IIa clinical trial to evaluate the safety and efficacy of tanibirumab (VEGFR2 mAb), in patients with recurrent glioblastoma (GBM).
2017
-
Efficacy analysis of ABT-414 with or without temozolomide (TMZ) in patients (pts) with EGFR-amplified, recurrent glioblastoma (rGBM) from a multicenter, international phase I clinical trial.
2017
-
A phase I dose-escalation study of BGB-A317, an anti-programmed death-1 (PD-1) mAb in patients with advanced solid tumors.
2016
-
Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, as monotherapy in epidermal growth factor receptor (EGFR) amplified, recurrent glioblastoma (GBM).
2016
-
Improved use of clinical variables for prognosis of distant recurrence in patients with ER+ breast cancer treated with 5 years endocrine therapy.
2016
-
Phase 2 study to evaluate the clinical efficacy and safety of MEDI4736 (durvalumab) in patients with glioblastoma (GBM).
2016
-
The clinical impact of sarcopaenia on chemotherapy delivery for gastric and oesophageal cancers.
2016
-
A phase I dose-escalation study of BGB-290, a novel PARP1/2 selective inhibitor in patients with advanced solid tumors.
2016
-
Efficacy and toxicity of treatment with the anti-CTLA-4 antibody Ipilimumab in patients with metastatic melanoma who have progressed on anti-PD-1 therapy
2015
-
Phase II study to evaluate the clinical efficacy and safety of MEDI4736 in patients with glioblastoma (GBM).
2015
-
cMet: Results in papillary renal cell carcinoma of a phase I study of AZD6094/volitinib leading to a phase 2 clinical trial with AZD6094/volitinib in patients with advanced papillary renal cell cancer (PRCC).
2015
-
Phase I study of ABT-414 mono- or combination therapy with temozolomide (TMZ) in recurrent glioblastoma (GBM)
2015
-
A phase 1 study evaluating ABT-414 in combination with temozolomide (TMZ) for subjects with recurrent or unresectable glioblastoma (GBM)
2014
-
First-in-human phase I study of a selective c-Met inhibitor volitinib (HMP504/AZD6094) in patients with advanced solid tumors.
2014
-
Safety and efficacy of eribulin mesylate (EM) in patients with advanced breast cancer: The Royal Marsden experience.
2014
-
Single nucleotide polymorphisms (SNPs) in vascular endothelial growth factor (VEGF) family genes as predictive or prognostic biomarkers in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of the phase III MAX Inter study.
2014
-
Effect of RAD21 overexpression on prognosis in KRAS-mutant colorectal carcinomas
2014
-
Effect of pregnant sera and a pregnancy-associated metalloproteinase (PAPP-A) on melanoma in vitro and in vivo: Insights into melanoma progression during pregnancy and potential new therapeutic targets.
2014
-
Myocardial strain for detection of treatment-related cardiac dysfunction in adult survivors of childhood cancer: Results from the St. Jude lifetime cohort study.
2014
-
Perceptions of radiation oncologists and urologists about new technology for the treatment of prostate cancer.
2014
-
Phase II study of everolimus monotherapy as first-line treatment in advanced biliary tract cancer: RADichol.
2014
-
ALK and ROS1 gene rearrangements detected in colorectal cancer (CRC) by fluorescence in situ hybridization (FISH)
2013
-
Effects of angiotensin-converting enzyme (ACE) inhibitors on the outcomes of patients receiving primary radiotherapy for prostate cancer (PC).
2013
-
A phase I and biodistribution study of ABT-806i, an (111)indium-labeled conjugate of the tumor-specific anti-EGFR antibody ABT-806.
2013
-
A phase I imaging and pharmacodynamic trial of CS-1008 in patients (pts) with metastatic colorectal cancer (mCRC).
2013
-
Hypoxia-inducible factor 1 alpha: A screening tool for predicting development of castrate resistant prostate cancer.
2012
-
Phase I clinical and pharmacologic study of the focal adhesion kinase (FAK) inhibitor GSK2256098 in pts with advanced solid tumors
2012
-
Pretreatment neurocognitive function (NCF) status in head and neck cancer (HNC) patients (pts) with comparison to control cohort
2012
-
The kinetics of the excision repair cross-complementing group-1 (ERCC1) gene in patients with colorectal cancer
2012
-
11C-choline PET scanning is more accurate than biopsy in assessment of localized prostate cancer planned for radical prostatectomy.
2012
-
A pilot study of the safety, efficacy, and effects on functional imaging of the combination of cG250 and sunitinib in patients (pts) with advanced renal cell carcinoma (RCC).
2011
-
Anti-LeY monoclonal antibody (mAb) hu3S193 (Rebmab 100) in patients with advanced platinum resistant/refractory (PRR) ovarian cancer (OC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC).
2011
-
Classification of the components of the MedDietScore in relation to colorectal cancer prevalence.
2011
-
Evaluation of second-line response to targeted therapy following progression on first-line cediranib, an oral pan-vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI), in advanced renal cell carcinoma (RCC).
2011
-
Expected benefits versus actual outcomes in oncology phase III randomized controlled trials (RCTs).
2011
-
Neurocognitive function (NCF) in patients (pts) treated with chemo/bio-radiotherapy (C/B-RT) for head and neck cancers (HNC).
2011
-
Vascular endothelial growth factors (VEGF) and VEGF receptor expression as predictive biomarkers for benefit with bevacizumab in metastatic colorectal cancer (mCRC): Analysis of the phase III MAX study.
2011
-
Adequacy of data provision and analysis in oncology phase III trials over the past 5 years.
2010
-
Antibody targeting of epithelial carcinoma-associated fibroblast activation protein blocks cellular proliferation, migration, and invasion.
2010
-
Association of Lynch syndrome and risk of invasive cervical cancer.
2010
-
Beyond KRAS: The quest for novel genetic markers predictive for response to anti-epidermal growth factor receptor (EGFR) therapy in patients with metastatic colorectal cancer (mCRC).
2010
-
Clinical predictors for emesis in breast cancer patients receiving anthracycline-based chemotherapy: Do Asians measure up?
2010
-
Cognitive functioning pre- and postradiotherapy (RT), chemoradiotherapy (CRT), or bioradiotherapy (BRT) in patients with locally advanced squamous cell cancer of the head and neck (LA-SCCHN).
2010
-
Consistency in reporting of primary endpoints (PEP) from registration to publication for modern randomized oncology phase III trials.
2010
-
DUX study: A phase II study of evaluating dual targeting of the EGFR using the combination of cetuximab and erlotinib in patients with chemotherapy refractory metastatic colorectal cancer.
2010
-
Evaluation of inducible expression of ERCC1 as a biomarker of drug response in human colorectal cancer cell lines.
2010
-
Phase I dose-escalation study of daily BMS-754807, an oral, dual IGF-1R/insulin receptor (IR) inhibitor in subjects with solid tumors
2010
-
Contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers and other high-risk women in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab)
2009
-
Neurocognitive outcomes of head and neck chemoradiotherapy: A pilot study
2009
-
Reporting of endpoints and tracking of failures in randomized trials of radiotherapy or concurrent chemoradiotherapy for locally advanced head and neck squamous cell cancer (LA-HNSCC)
2009
-
Staging (18)FDG-PET in newly diagnosed small cell lung cancer (SCLC): 15-year institutional experience
2009
-
A phase II trial of temolozomide in patients with untreated high grade oligodengroglial brain tumours
2008
-
Complementary and alternative medicine (CAM) use in high-risk women in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab)
2008
-
Phase I biodistribution study of Ley targeting immunoconjugate in advanced epithelial cancers
2008
-
Synergistic therapeutic activity of chimeric G250-TNF and IFNγ for the treatment of renal cell cancer
2008
-
F-18-FDG PET changes management and improves prognostic stratification in patients with colorectal cancer: results of a prospective, multi-centre study
2007
-
Multi-centre prospective assessment of accuracy and impact on management of positron emission tomography (PET) in esophageal and gastroesophageal junction cancers (EC). Australian PET Data Collection Project
2007
-
Targeted chemoradiation for metastatic colorectal cancer: A phase I trial of oral capecitabine combined with I-131-huA33
2007
-
Cancer risk management practices of non-carriers within BRCA1/2 mutation positive families in the Kathleen Cunningham Consortium for Research into Familial Breast Cancer (kConFab).
2006
-
Phase I study of CHP-HER2 polyvalent cancer vaccine, HER2 protein combined with a novel nanoparticle antigen delivery system of cholesteryl hydrophobized polysaccharides.
2005
-
A phase I trial of humanized monoclonal antibody huA33 in patients with early gastric cancer: Imaging studies, biodistribution, pharmacolkinetics, immunohistochemistry, and quantitative tumor uptake
2004
-
Phase I trial of hu3S193 in patients with advanced epithelial cancers which express the Lewis-y antigen.
2004
-
The utility of in-vivo functional and genetic parameters of drug elimination for the estimation of irinotecan (Ir) clearance (CL).
2004
-
Combination of CDK and Bcl-2 inhibitors in the treatment of soft-tissue sarcomas
2018
-
Vascular endothelial growth factors (VEGF) and VEGF receptor expression as predictive biomarkers for benefit with bevacizumab in metastatic colorectal cancer (mCRC): Analysis of the phase III MAX study.
2011
has subject area
Identity
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)